Phase II, Open-label Study to Assess the Safety and Efficacy of Oral MEK162 in Adults With Locally Advanced and Unresectable or Metastatic Malignant Cutaneous Melanoma, Harboring BRAFV600E or NRAS Mutations

Trial Profile

Phase II, Open-label Study to Assess the Safety and Efficacy of Oral MEK162 in Adults With Locally Advanced and Unresectable or Metastatic Malignant Cutaneous Melanoma, Harboring BRAFV600E or NRAS Mutations

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Binimetinib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Array BioPharma; Novartis
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 26 May 2017 Planned End Date changed from 30 Jun 2017 to 30 Jun 2018.
    • 30 Jan 2017 Planned End Date changed from 1 Dec 2016 to 30 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top